Intellia Therapeutics (NASDAQ:NTLA) Given Neutral Rating at William Blair

Intellia Therapeutics (NASDAQ:NTLA)‘s stock had its “neutral” rating reissued by equities researchers at William Blair in a research note issued on Monday,RTT News reports. They presently have a $14.00 price objective on the stock. William Blair’s price target suggests a potential upside of 0.65% from the company’s previous close.

A number of other analysts have also recently commented on NTLA. Evercore ISI raised Intellia Therapeutics to a “strong-buy” rating in a research note on Friday, August 9th. Barclays lowered their price objective on shares of Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating for the company in a research report on Friday, November 8th. Stifel Nicolaus lowered their target price on Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating for the company in a research note on Wednesday, September 11th. JPMorgan Chase & Co. cut their price objective on shares of Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. Finally, Chardan Capital boosted their target price on Intellia Therapeutics from $88.00 to $91.00 and gave the company a “buy” rating in a research note on Monday. One analyst has rated the stock with a sell rating, six have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Intellia Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $52.80.

Intellia Therapeutics Stock Performance

NTLA traded down $0.06 during midday trading on Monday, hitting $13.91. The company had a trading volume of 2,678,379 shares, compared to its average volume of 1,685,642. The company has a market capitalization of $1.42 billion, a PE ratio of -2.58 and a beta of 1.81. The firm’s 50-day simple moving average is $18.64 and its 200-day simple moving average is $22.04. Intellia Therapeutics has a twelve month low of $13.54 and a twelve month high of $34.87.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.37) by $0.03. The firm had revenue of $9.10 million for the quarter, compared to the consensus estimate of $8.28 million. During the same period in the prior year, the firm posted ($1.38) earnings per share. The business’s revenue for the quarter was down 24.1% compared to the same quarter last year. As a group, sell-side analysts anticipate that Intellia Therapeutics will post -5.13 EPS for the current fiscal year.

Insider Activity at Intellia Therapeutics

In related news, CAO Michael P. Dube sold 2,012 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total value of $38,248.12. Following the completion of the transaction, the chief accounting officer now owns 47,012 shares of the company’s stock, valued at $893,698.12. This represents a 4.10 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 3.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. State Street Corp grew its holdings in Intellia Therapeutics by 17.9% during the 3rd quarter. State Street Corp now owns 5,143,534 shares of the company’s stock worth $105,700,000 after acquiring an additional 780,754 shares during the last quarter. Vanguard Group Inc. raised its position in Intellia Therapeutics by 8.9% during the 1st quarter. Vanguard Group Inc. now owns 9,093,712 shares of the company’s stock worth $250,168,000 after purchasing an additional 746,263 shares during the last quarter. ARK Investment Management LLC lifted its holdings in Intellia Therapeutics by 5.7% during the 3rd quarter. ARK Investment Management LLC now owns 12,255,440 shares of the company’s stock worth $251,849,000 after buying an additional 659,651 shares during the period. Federated Hermes Inc. lifted its stake in shares of Intellia Therapeutics by 19.2% in the second quarter. Federated Hermes Inc. now owns 2,300,889 shares of the company’s stock worth $51,494,000 after acquiring an additional 371,189 shares during the period. Finally, Two Sigma Advisers LP boosted its stake in shares of Intellia Therapeutics by 33.5% in the 3rd quarter. Two Sigma Advisers LP now owns 1,027,617 shares of the company’s stock valued at $21,118,000 after purchasing an additional 257,700 shares during the last quarter. 88.77% of the stock is currently owned by institutional investors and hedge funds.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.